文献速递前列腺癌

pT2前列腺癌亚分期对根治性前列腺切除术后预后无判别价值

Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
PubMed 文献 · J Urol · 2018-01-04

该回顾性研究纳入2个转诊中心1985至2016年间15,305例根治性前列腺切除术后病理为pT2的前列腺癌患者,比较pT2a/b与pT2c的生存相关结局。中位随访6.0年,单因素分析显示pT2亚分期与生化复发(p=0.001)和远处转移(p=0.033)相关,但多因素分析无显著关联(p=0.4和p=0.6);与癌症特异性死亡和总死亡率无显著关联。结论认为pT2亚分期不是根治性前列腺切除术后生存相关结局的预后指标,支持新版分期系统取消pT2亚分期。

要点

  • pT2亚分期与生化复发和远处转移在单因素分析中相关,但多因素分析无显著关联。
  • pT2亚分期与癌症特异性死亡(p=0.6)和总死亡率(p=0.3)无显著关联。
  • 结果支持新版前列腺癌分期系统取消pT2亚分期。

核心结论

  • pT2前列腺癌亚分期不是根治性前列腺切除术后生存相关结局的预后指标,验证了新版分期系统取消pT2亚分期的合理性。

研究设计与样本

  • 回顾性分析2个转诊中心1985至2016年间15,305例根治性前列腺切除术后病理为pT2的前列腺癌患者,比较pT2a/b与pT2c亚组,采用Cox回归模型分析生化复发、转移、癌症特异性死亡和总死亡率。

主要发现

  • pT2a/b与pT2c亚组间前列腺特异性抗原水平和Gleason评分差异显著(各p<0.0001)。
  • 中位随访6.0年(IQR 3.3-10.1),2,083例出现生化复发,161例发生转移,43例死于前列腺癌,1,032例死于其他原因。
  • 单因素分析中pT2亚分期与生化复发(p=0.001)和远处转移(p=0.033)显著相关,但与癌症特异性死亡(p=0.6)和总死亡率(p=0.3)无显著关联。
  • 多因素分析显示pT2亚分期与生化复发(p=0.4)或远处转移(p=0.6)无显著关联。

关键数值与推荐

  • pT2亚分期与生化复发多因素分析p=0.4,与远处转移多因素分析p=0.6,均无显著关联。

临床怎么用

  • 根治性前列腺切除术后病理为pT2的前列腺癌患者,pT2亚分期(pT2a/b vs pT2c)不提供生存相关结局的预后判别信息。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We tested the latest update in the prostate cancer staging system by assessing the prognostic association of pT2 subclassification with the probability of survival related outcomes in patients who underwent radical prostatectomy. MATERIALS AND METHODS: We retrospectively analyzed the records of a total of 15,305 patients who underwent radical prostatectomy at 2 referral centers between 1985 and 2016, and had pT2 disease at the final pathological evaluation. Descriptive statistics were used to compare baseline data stratified by pT2 substages (pT2a/b vs pT2c). Cox regression models were adjusted for institution analyzed differences in the rate of biochemical recurrence, metastasis, cancer specific death and overall mortality. Multivariable Cox regression models were used to evaluate the predictive value of pT2 subclassification for survival, including the linear predictor from the Stephenson nomogram. RESULTS: Prostate specific antigen levels and Gleason score differed significantly between the pT2 substages (each p <0.0001). At a median followup of 6.0 years (IQR 3.3-10.1) 2,083 patients had biochemical recurrence, 161 had metastases, 43 had died of prostate cancer and 1,032 had died of another cause. On univariate analysis the pT2 subclassification was significantly associated with biochemical recurrence (p = 0.001) and distant metastasis (p = 0.033) but not with cancer specific death (p = 0.6) or overall mortality (p = 0.3). Multivariable analysis showed no evidence of a significant association between the pT2 subclassification and biochemical recurrence (p = 0.4) or distant metastasis (p = 0.6). Multivariable analysis of cancer specific death and overall mortality was omitted due to lack of significance on univariate analysis. CONCLUSIONS: Subclassification of pT2 prostate cancer is not a prognostic indicator of survival related outcomes after radical prostatectomy. Our results validate the elimination of pT2 substages in the updated staging system.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Nguyen DP, Vertosick EA, Sharma V, et al. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy? J Urol. 2018. PMID: 29307681. doi:10.1016/j.juro.2017.12.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。